Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urethral Stricture | 56 | 2025 | 58 | 18.470 |
Why?
|
| Urethra | 44 | 2025 | 60 | 9.750 |
Why?
|
| Urologic Surgical Procedures, Male | 36 | 2025 | 47 | 6.150 |
Why?
|
| Mouth Mucosa | 11 | 2025 | 23 | 4.260 |
Why?
|
| Lichen Sclerosus et Atrophicus | 9 | 2025 | 11 | 4.210 |
Why?
|
| Urinary Fistula | 8 | 2022 | 16 | 3.120 |
Why?
|
| Surgical Flaps | 10 | 2023 | 112 | 2.560 |
Why?
|
| Urethral Diseases | 8 | 2022 | 12 | 2.320 |
Why?
|
| Rectal Fistula | 5 | 2022 | 19 | 2.250 |
Why?
|
| Postoperative Complications | 18 | 2024 | 1169 | 1.950 |
Why?
|
| Retrospective Studies | 51 | 2025 | 6125 | 1.830 |
Why?
|
| Prostatic Neoplasms | 9 | 2022 | 330 | 1.660 |
Why?
|
| Radiation Injuries | 5 | 2021 | 62 | 1.650 |
Why?
|
| Male | 74 | 2025 | 27916 | 1.470 |
Why?
|
| Endoscopy | 6 | 2021 | 104 | 1.330 |
Why?
|
| Intestinal Mucosa | 4 | 2021 | 225 | 1.300 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2020 | 5 | 1.290 |
Why?
|
| Gracilis Muscle | 2 | 2020 | 3 | 1.230 |
Why?
|
| Humans | 93 | 2025 | 60049 | 1.210 |
Why?
|
| Middle Aged | 49 | 2025 | 16503 | 1.200 |
Why?
|
| Pubic Symphysis | 2 | 2019 | 4 | 1.200 |
Why?
|
| Cystoscopy | 7 | 2020 | 13 | 1.130 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 111 | 1.110 |
Why?
|
| Urinary Incontinence | 4 | 2024 | 39 | 1.090 |
Why?
|
| Robotics | 3 | 2019 | 54 | 1.030 |
Why?
|
| Urethral Neoplasms | 2 | 2016 | 3 | 1.020 |
Why?
|
| Pelvic Bones | 6 | 2022 | 14 | 1.020 |
Why?
|
| Hematuria | 2 | 2024 | 20 | 1.000 |
Why?
|
| Rivaroxaban | 1 | 2024 | 22 | 0.940 |
Why?
|
| Adult | 43 | 2025 | 15952 | 0.930 |
Why?
|
| Recurrence | 14 | 2024 | 599 | 0.910 |
Why?
|
| Aged | 36 | 2025 | 13553 | 0.900 |
Why?
|
| Urinary Bladder | 3 | 2018 | 36 | 0.850 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2023 | 6 | 0.840 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 216 | 0.820 |
Why?
|
| Urologic Surgical Procedures | 9 | 2022 | 22 | 0.810 |
Why?
|
| Treatment Outcome | 22 | 2025 | 5258 | 0.800 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2019 | 23 | 0.800 |
Why?
|
| Urinary Retention | 1 | 2022 | 31 | 0.760 |
Why?
|
| Wounds and Injuries | 2 | 2016 | 243 | 0.750 |
Why?
|
| Fractures, Bone | 5 | 2022 | 144 | 0.740 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 5181 | 0.740 |
Why?
|
| Ejaculation | 2 | 2021 | 8 | 0.730 |
Why?
|
| Surgeons | 1 | 2023 | 157 | 0.720 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 2361 | 0.710 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2025 | 125 | 0.700 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2010 | 6 | 0.700 |
Why?
|
| Anticoagulants | 1 | 2024 | 487 | 0.690 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 9 | 0.670 |
Why?
|
| Osteomyelitis | 1 | 2019 | 23 | 0.660 |
Why?
|
| Penile Diseases | 3 | 2025 | 6 | 0.650 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2017 | 36 | 0.630 |
Why?
|
| Contracture | 1 | 2017 | 8 | 0.580 |
Why?
|
| Reoperation | 6 | 2021 | 266 | 0.570 |
Why?
|
| Mitomycin | 2 | 2020 | 25 | 0.550 |
Why?
|
| Urogenital System | 1 | 2016 | 3 | 0.540 |
Why?
|
| Urologic Diseases | 1 | 2016 | 11 | 0.530 |
Why?
|
| Urinary Incontinence, Urge | 4 | 2022 | 4 | 0.530 |
Why?
|
| Rectus Abdominis | 1 | 2016 | 2 | 0.520 |
Why?
|
| Fistula | 1 | 2016 | 13 | 0.520 |
Why?
|
| Prostatic Diseases | 1 | 2016 | 8 | 0.520 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 58 | 0.520 |
Why?
|
| Joint Diseases | 1 | 2016 | 18 | 0.510 |
Why?
|
| Microsurgery | 1 | 2016 | 52 | 0.510 |
Why?
|
| Urology | 4 | 2024 | 28 | 0.500 |
Why?
|
| MicroRNAs | 1 | 2021 | 620 | 0.500 |
Why?
|
| Cystostomy | 3 | 2022 | 3 | 0.480 |
Why?
|
| Anastomosis, Surgical | 6 | 2021 | 104 | 0.470 |
Why?
|
| Disease Management | 1 | 2016 | 221 | 0.470 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 50 | 0.460 |
Why?
|
| Quality of Life | 6 | 2025 | 1139 | 0.440 |
Why?
|
| Algorithms | 1 | 2018 | 1001 | 0.430 |
Why?
|
| Urinary Sphincter, Artificial | 3 | 2022 | 3 | 0.420 |
Why?
|
| Rectum | 3 | 2019 | 85 | 0.420 |
Why?
|
| Urethral Obstruction | 2 | 2022 | 6 | 0.410 |
Why?
|
| Cohort Studies | 9 | 2024 | 2479 | 0.400 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 239 | 0.400 |
Why?
|
| Urinary Tract Infections | 3 | 2022 | 79 | 0.390 |
Why?
|
| Nephrectomy | 1 | 2012 | 49 | 0.390 |
Why?
|
| Trauma Centers | 2 | 2012 | 119 | 0.380 |
Why?
|
| Preoperative Period | 3 | 2020 | 61 | 0.380 |
Why?
|
| Minimally Invasive Surgical Procedures | 5 | 2019 | 93 | 0.380 |
Why?
|
| Biomarkers | 3 | 2023 | 1212 | 0.370 |
Why?
|
| Risk Factors | 9 | 2024 | 5068 | 0.370 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2022 | 23 | 0.370 |
Why?
|
| Ileostomy | 1 | 2010 | 25 | 0.360 |
Why?
|
| Prostatectomy | 5 | 2024 | 51 | 0.350 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 418 | 0.350 |
Why?
|
| Young Adult | 8 | 2020 | 4384 | 0.340 |
Why?
|
| Penile Induration | 1 | 2009 | 2 | 0.340 |
Why?
|
| Dilatation | 2 | 2021 | 31 | 0.330 |
Why?
|
| Kidney | 1 | 2012 | 395 | 0.330 |
Why?
|
| Ileum | 1 | 2009 | 21 | 0.330 |
Why?
|
| Severity of Illness Index | 7 | 2024 | 1471 | 0.330 |
Why?
|
| Female | 12 | 2024 | 31193 | 0.320 |
Why?
|
| Cystectomy | 3 | 2019 | 18 | 0.320 |
Why?
|
| Urinary Diversion | 3 | 2017 | 8 | 0.320 |
Why?
|
| Risk Assessment | 6 | 2024 | 1933 | 0.310 |
Why?
|
| Urography | 2 | 2020 | 13 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2024 | 3126 | 0.310 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 3 | 0.300 |
Why?
|
| Urination | 4 | 2022 | 13 | 0.300 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 37 | 0.290 |
Why?
|
| Radiotherapy | 2 | 2020 | 65 | 0.290 |
Why?
|
| Laparoscopy | 2 | 2010 | 396 | 0.290 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 108 | 0.290 |
Why?
|
| Sexual Behavior | 2 | 2019 | 185 | 0.290 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 360 | 0.290 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 710 | 0.280 |
Why?
|
| Time Factors | 5 | 2019 | 3610 | 0.270 |
Why?
|
| Inflammation | 2 | 2024 | 1109 | 0.260 |
Why?
|
| Urodynamics | 3 | 2018 | 13 | 0.260 |
Why?
|
| Enoxaparin | 1 | 2024 | 16 | 0.240 |
Why?
|
| Penis | 3 | 2022 | 21 | 0.230 |
Why?
|
| Cystitis | 1 | 2023 | 9 | 0.220 |
Why?
|
| Fibrosis | 1 | 2024 | 152 | 0.220 |
Why?
|
| Incidence | 2 | 2024 | 1255 | 0.220 |
Why?
|
| Causality | 1 | 2023 | 56 | 0.220 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 17 | 0.220 |
Why?
|
| Learning Curve | 2 | 2015 | 27 | 0.220 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 852 | 0.210 |
Why?
|
| Surveys and Questionnaires | 4 | 2018 | 2613 | 0.200 |
Why?
|
| Multiple Trauma | 1 | 2022 | 27 | 0.200 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 110 | 0.200 |
Why?
|
| Wound Infection | 1 | 2022 | 26 | 0.190 |
Why?
|
| Genetic Markers | 1 | 2021 | 122 | 0.190 |
Why?
|
| Tissue Array Analysis | 2 | 2019 | 31 | 0.190 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2021 | 23 | 0.190 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2021 | 1 | 0.180 |
Why?
|
| Scrotum | 2 | 2022 | 6 | 0.180 |
Why?
|
| Conservative Treatment | 1 | 2021 | 14 | 0.180 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 16 | 0.180 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2020 | 16 | 0.180 |
Why?
|
| Phenotype | 1 | 2024 | 1157 | 0.170 |
Why?
|
| Debridement | 1 | 2019 | 30 | 0.170 |
Why?
|
| Colon | 1 | 2021 | 139 | 0.170 |
Why?
|
| Risk Adjustment | 1 | 2020 | 94 | 0.170 |
Why?
|
| Sex Reassignment Surgery | 1 | 2019 | 5 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2025 | 531 | 0.160 |
Why?
|
| Male Urogenital Diseases | 1 | 2018 | 5 | 0.150 |
Why?
|
| Adolescent | 5 | 2020 | 5950 | 0.150 |
Why?
|
| Autografts | 1 | 2018 | 8 | 0.150 |
Why?
|
| Fracture Fixation, Internal | 1 | 2018 | 49 | 0.150 |
Why?
|
| Biopsy | 1 | 2019 | 376 | 0.150 |
Why?
|
| Prognosis | 3 | 2019 | 1589 | 0.150 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2008 | 24 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 248 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 62 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 74 | 0.140 |
Why?
|
| United States | 7 | 2024 | 7595 | 0.140 |
Why?
|
| Injections, Intralesional | 2 | 2020 | 13 | 0.140 |
Why?
|
| Urination Disorders | 1 | 2016 | 8 | 0.140 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 295 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2024 | 746 | 0.130 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2016 | 5 | 0.130 |
Why?
|
| Lymphedema | 1 | 2016 | 7 | 0.130 |
Why?
|
| Injury Severity Score | 2 | 2018 | 102 | 0.130 |
Why?
|
| Tissue Engineering | 1 | 2018 | 135 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 712 | 0.130 |
Why?
|
| Rheology | 1 | 2016 | 69 | 0.130 |
Why?
|
| Infant | 1 | 2020 | 1529 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2020 | 1845 | 0.120 |
Why?
|
| Anxiety | 1 | 2018 | 400 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 465 | 0.120 |
Why?
|
| Recovery of Function | 3 | 2019 | 267 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2012 | 52 | 0.100 |
Why?
|
| Abdominal Injuries | 1 | 2012 | 30 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 103 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 70 | 0.090 |
Why?
|
| Depression | 1 | 2018 | 868 | 0.090 |
Why?
|
| Child | 1 | 2020 | 4328 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 83 | 0.090 |
Why?
|
| Psychometrics | 2 | 2025 | 359 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2010 | 210 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 341 | 0.080 |
Why?
|
| Cadherins | 1 | 2008 | 68 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 1565 | 0.080 |
Why?
|
| Acute Disease | 1 | 2009 | 661 | 0.070 |
Why?
|
| Silver | 1 | 2007 | 13 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 675 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 88 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2012 | 851 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2007 | 58 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2007 | 33 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 43 | 0.070 |
Why?
|
| Critical Care | 1 | 2010 | 417 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2007 | 213 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 736 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2019 | 849 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 1524 | 0.060 |
Why?
|
| Metal Nanoparticles | 1 | 2007 | 181 | 0.060 |
Why?
|
| Personnel Selection | 1 | 2024 | 49 | 0.060 |
Why?
|
| Prevalence | 2 | 2018 | 1292 | 0.050 |
Why?
|
| Fascia | 1 | 2022 | 5 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 789 | 0.050 |
Why?
|
| Obesity | 2 | 2022 | 1190 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 272 | 0.050 |
Why?
|
| Nitrofurantoin | 1 | 2020 | 10 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2021 | 43 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1235 | 0.040 |
Why?
|
| Cryosurgery | 1 | 2020 | 24 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 69 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 59 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 79 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 166 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 203 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 264 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 230 | 0.040 |
Why?
|
| Device Removal | 1 | 2020 | 61 | 0.040 |
Why?
|
| Perineum | 1 | 2019 | 19 | 0.040 |
Why?
|
| Abbreviated Injury Scale | 1 | 2018 | 13 | 0.040 |
Why?
|
| Urinary Catheters | 1 | 2018 | 5 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 257 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pathologists | 1 | 2018 | 12 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 209 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 129 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 126 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 377 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1035 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 281 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 391 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 15 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2008 | 557 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 2016 | 13 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2016 | 51 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 58 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 68 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 40 | 0.030 |
Why?
|
| California | 1 | 2016 | 162 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2016 | 152 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1094 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 206 | 0.030 |
Why?
|
| Vagina | 1 | 2014 | 83 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 564 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2018 | 698 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1100 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 717 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 805 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1301 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 514 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2491 | 0.020 |
Why?
|
| Catenins | 1 | 2007 | 10 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2007 | 59 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 21 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2007 | 30 | 0.020 |
Why?
|
| Materials Testing | 1 | 2007 | 81 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 676 | 0.020 |
Why?
|
| Cell Movement | 1 | 2008 | 425 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 191 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2007 | 209 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 597 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 458 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2007 | 161 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 855 | 0.010 |
Why?
|